OxidoCurin

Targets and biomarkers of the novel anticancer compounds inducing oxidative stress in cancer cells

Europa

EUREKA

 

 

 

As a Eurostars project, OxidoCurin is an international, SME-driven project for innovative product development with a fast track to market.

The project aims at further developing a novel anti-cancer lead compound, to make it suitable for application in preclinical and later clinical trials. Starting point will be a previously chacterized lead compound. To provide all preconditions for future exploitation, the target(s) of the compound will be experimentally validated by different methods, among them state-of the-art TPP (thermal proteome profiling) methodology.
Elucidating the mechanism of interaction of the lead compound with its target(s) will enable to identify its mechanism of action. Further efforts will be made to identify biomarkers of sensitivity and resistance of cancer cells and the mechanism of possible toxic side effects.

Further information

Contract no.

01QE1751A

Contract period

2017-10-01 to 2020-09-30

Coordinator

The project is coordinated by Dr. Alexander Kel, geneXplain GmbH, Wolfenb├╝ttel, Germany

×
This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
536